// App-Quantinova.ai

P6-04-01 : A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer

Researchers

Presenter

  • John FR Robertson

Principal Investigators

  • Stephan Henschen

  • Cliona Kirwan

  • Ali Jahan

  • Laura Kenny

  • J. Michael Dixon

  • Peter Schmid

  • Ashutosh Kothari

  • Omar Mohamed

  • Peter A Fasching

  • Kwok-Leung Cheung

  • Rachel Wuerstlein

  • Danielle Carroll

  • Teresa Klinowska

  • Justin PO Lindemann

  • Alexander MacDonald

  • Richard Mather

  • Rhiannon Maudsley

  • Michele Moschetta

  • Myria Nikolaou

  • Martine P Roudier

  • Tinnu Sarvotham

  • Gaia Schiavon

  • Diansong Zhou

  • Li Zhou

  • Nadia Harbeck

Medical Centers

  • University of Nottingham, Nottingham, United Kingdom

  • Poole Hospital, UK, Poole, United Kingdom

  • Helios Kliniken Schwerin, Schwerin, Germany

  • Wythenshawe Hospital, Manchester, United Kingdom

  • King's Mill Hospital, Mansfield, United Kingdom

  • Imperial College London, Imperial Health Care NHS Trust, London, United Kingdom

  • Western General Hospital, Edinburgh, United Kingdom

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Johannes Wesling General Hospital, Minden, Germany

  • Women's Hospital of the University Hospital Erlangen, Erlangen, Germany

  • University of Munich, Munich, Germany

  • Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Progesterone receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Fulvestrant

  • AZD-9496

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • I

Study Id's

  • NCT03236974

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved